ION455 / Ionis - LARVOL DELTA

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. (clinicaltrials.gov) - P1 | N=40 | Terminated | Sponsor: AstraZeneca | N=60 ➔ 40 | Trial completion date: Oct 2024 ➔ Mar 2024 | Recruiting ➔ Terminated; AstraZeneca have decided to not move forward with the development of the compound.

Enrollment change • Trial completion date • Trial termination • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants. (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=19 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants. (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants. (clinicaltrials.gov) - P1 | N=11 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: AstraZeneca | N=14 ➔ 20

Enrollment change • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jun 2024 ➔ Oct 2024

Trial completion date • Hepatology • Non-alcoholic Steatohepatitis

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting | Trial completion date: Jan 2023 ➔ Dec 2023 | Trial primary completion date: Jan 2023 ➔ Dec 2023

Enrollment open • Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: AstraZeneca

New P1 trial • Hepatology • Non-alcoholic Steatohepatitis

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=8 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Jan 2023 | Trial primary completion date: Aug 2023 ➔ Jan 2023

Enrollment closed • Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=5 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2023 ➔ Aug 2023 | Trial primary completion date: Mar 2023 ➔ Aug 2023

Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=5 | Recruiting | Sponsor: AstraZeneca

New P1 trial • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2023 ➔ Nov 2022

Enrollment closed • Trial completion date

"Does not bode well for NASH assets ION839 and ION455🤔 🤞" (@dr_muniyappa)

Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2022 ➔ Feb 2023

Trial completion date